I t has been almost 15 years since the publication of the landmark National Institute of Neurological Disorders and Stroke tissue plasminogen activator (NINDS-tPA) trial. The findings of the NINDS-tPA trial soon led to Food and Drug Administration (FDA) approval for IV alteplase (tPA) in the treatment of acute ischemic stroke (AIS) that transformed the way neurologists approach this devastating disease. Unfortunately, 15 years removed from the NINDS-tPA trial, IV tPA remains the only FDA-approved drug for the treatment of AIS. Although no major clinical breakthrough has occurred in the AIS treatment front, newer trials have increased the spectrum of patients who can be treated, but failed to find better lytic drugs or ways to identify treatable patients using advanced imaging. Major advancements have transpired in the arena of stroke prevention, especially in endovascular therapy and management of atrial fibrillation (AF). This article aims to summarize 5 new topics in stroke treatment, prevention, and poststroke care that have or will soon affect clinical treatment of stroke patients, and to offer critiques and commentary on how the results of the trials presented can be applied to the care of individual stroke patients.
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Major advancements have transpired in the arena of stroke prevention, especially in endovascular therapy and management of atrial fibrillation
Not surprisingly, the issue of CEA vs CAS and the interpretation of the CREST results are still debated within the neurovascular community. Although the results showed that there were no differences between the procedures in achieving the primary outcome (any stroke, MI, death), it is important to highlight that stroke, which one can argue has a stronger effect on quality of life than a nonfatal MI, was more likely after CAS. The increased risk of ischemic events with CAS was also observed in the International Carotid Stenting Study trial: 7.7% for CAS and 4.1% for CEA (HR for stenting 1.92; 95% CI 1.27-2.89; p ϭ 0.002) 4 and a substudy of the International Carotid Stenting Study trial using MRI-DWI showed 3 times more patients in the CAS group than in the CEA group had new ischemic lesions on posttreatment MRI scans. 5 While the CREST trial has shown that both procedures can be done safely and are durable, at least up to 4 years, it is important to underscore that the procedures in the trial were performed by highly qualified interventionists or surgeons, which may not be available at all centers. In addition, there are other factors that may also influence treatment selection, such as location of the stenotic lesion and vessel accessibility. CREST has reinforced the robust utility of CEA and has also armed clinicians with another option to treat carotid disease, but we still need to individualize therapy to balance all risks and benefits. Clinicians have to take into account a multitude of clinical factors and also be familiar with the technical expertise of the local surgeon or interventionist in order to develop the best treatment strategy for each patient. At present, we tend to favor CAS in younger patients without extensive atherosclerosis and noncompliant vessels, and also in high surgical risk patients with bilateral disease (who are currently candidates for the ongoing Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy trial). We recommend CEA in most other patients.
NEW ORAL THERAPY FOR ATRIAL FIBRILLATION
It has been estimated that over 2 million Americans are affected by AF and more that 75,000 strokes each year can be attributed to AF. 6 Numerous trials have demonstrated the efficacy of warfarin in the treatment of AF for stroke prevention and it remains the mainstay therapy for this disease. Although efficacious, warfarin nevertheless has disadvantages that often limit its use in AF patients. Notably, warfarin causes major bleeding in 1.3% annually 1 and with the multitude of drug and food interactions and narrow therapeutic window, continuous close INR monitoring is required.
The Randomized Evaluation of Long-Term Anticoagulation Therapy trial 6 was a noninferiority trial that aimed to determine the incidence of systemic embolism in patients treated with warfarin or the new oral thrombin inhibitor, dabigatran. AF patients with risks for stroke were randomized to either 110 mg or 150 mg of dabigatran twice daily or adjusted dose warfarin (target INR 2.0 to 3.0). The primary clinical outcome was stroke or systemic embolism and the primary safety outcome was major bleeding defined as a reduction in the hemoglobin level of at least 20 g/L, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ. 6 In total, 18,113 patients were enrolled with a mean age of 71 years and the median follow-up was 2 years. Results showed that the primary clinical outcome was achieved in 1.53%/year of patients receiving 110 mg of dabigatran, 1.11%/year for 150 mg of dabigatran, and 1.69%/year for warfarin, with both doses of dabigatran demonstrating noninferiority to warfarin ( p Ͻ 0.001). High-dose dabigatran proved to be superior to warfarin (RR 0.66; 95% CI 0.74 -0.82; p Ͻ 0.001) in regards to the primary endpoint. The occurrence of hemorrhagic stroke was rare in all 3 groups but the rates were lower in the dabigatran group, which achieved statistical significance (0.38%/year warfarin, 0.12%/year 110 mg dabigatran, 0.10%/year 150 mg dabigatran).
Major bleeding was observed in 3.36%/year of warfarin-treated patients, as compared to 2.71%/year (RR 0.80; 95% CI 0.69 -0.93; p ϭ 0.003) in those treated with 110 mg dabigatran and 3.11%/year (RR 0.93; 95% CI 0.81-1.7; p ϭ 0.31) in the 150 mg dabigatran group. Overall, the combined outcome including major vascular events, major bleeding, and death was 7.64%/year in the warfarin group, 7.09%/year (RR 0.92; 95% CI 0.84 -1.02; p ϭ 0.10) with 110 mg of dabigatran, and 6.91%/year (RR 0.91; 95% CI 0.82-1.00; p ϭ 0.04) with 150 mg of dabigatran.
Clinical outcomes were comparable between all doses of dabigatran and warfarin, with the high-dose dabigatran outperforming warfarin. On the other hand, the low-dose dabigatran had lower major bleeding rates than warfarin, and similar major bleeding risks were observed between warfarin and high-dose dabigatran. Currently, dabigatran is not available in the United States but indications are that it will soon be reviewed by the FDA. The cost of dabigatran, which is estimated to be 5-10 times the cost of warfarin, may be a major barrier to its widespread use if approved by the FDA. However, the lack of mandatory INR monitoring and the potential of increasing medication compliance along with its superior efficacy and less risk would prevent more disabling strokes. The increased cost of dabigatran would be outweighed by a reduction in the longterm costs of stroke care. The results of this study are encouraging, and a safer and more effective (and cost-effective) treatment may soon be available for secondary stroke prevention in AF. We anticipate using the higher 150 mg dose in most patients, and the lower 110 mg dose in patients with higher bleeding risk.
EXTENDING THROMBOLYSIS BEYOND THE
3-HOUR TIME WINDOW Results from the 1995 NINDS-tPA trial showed that IV tPA initiated in patients within 3 hours of stroke onset was 30% more likely to achieve little or no disability up to a year after treatment compared to placebo. Despite the robust results of the NINDS-tPA trial, it is estimated that only 2%-5% of all stroke patients are treated with IV tPA nationally, 7, 8 largely due to delay in presentation to emergency departments. Subsequent analysis of the NINDS-tPA trial and 6 other prospective randomized tPA trials revealed that IV tPA may still be efficacious beyond 3 hours and up to 4.5 hours without unacceptable risk of hemorrhage or death.
The European Cooperative Acute Stroke Study III (ECASS III) was a randomized, placebocontrolled, phase 3 trial that aimed to assess the efficacy of IV tPA administered between 3 and 4.5 hours after stroke onset. 9 Patients aged 18 -80 years, with NIH Stroke Scale (NIHSS) score Յ25, with clinical diagnosis of AIS and able to receive the study drug within 3 to 4.5 hours were eligible for the trial. Major exclusion criteria included a combination of previous stroke and diabetes, severe strokes, and patients receiving warfarin even with normal INR. In total, 821 patients were enrolled and included in the intention-to-treat analysis with 418 assigned to tPA and 403 assigned to placebo.
The
). Secondary endpoint was a global outcome measure comprised of the composite of 90-day mRS of 0 or 1, Barthel Index Ն95, and NIHSS and Glasgow Outcome Score ϭ 0 or 1. Safety endpoints included mortality at 90 days, any intracranial hemorrhage, symptomatic intracranial hemorrhage (sICH), and symptomatic edema.
Demographics and baseline characteristics were fairly similar between the study group and the placebo arm, except that the initial NIHSS score was slightly higher in the placebo group (median of 9 tPA and 10 placebo; p ϭ 0.03) and the history of stroke was more prevalent in the control group (14.1% placebo vs 7.7% tPA; p ϭ 0.03). After adjustment for these confounding variables, treatment with tPA was associated with an increase in favorable outcome (odds ratio 1.42; 95% CI 1.02-1.98; p ϭ 0.04). Both intracranial hemorrhage (17.6% placebo vs 27% tPA, p ϭ 0.001) and the incidence of sICH (0.3% placebo vs 2.4% tPA, p ϭ 0.008) were more common in the tPA group.
In contrast to the NINDS-tPA trial, ECASS III excluded patients older than 80, those with NIHSS Ͼ25, patients taking oral anticoagulants, and patients with history of previous stroke and diabetes mellitus. The definition of sICH also differed between the 2 trials. In the NINDS-tPA trial, sICH was defined as a hemorrhage not seen on a previous CT scan causing any decline in neurologic status. ECASS III had a narrower definition of sICH, defined as a hemorrhage causing a decline in neurologic status by increasing the NIHSS by greater than 4 points or leading to death. Despite the differences in trial inclusion and exclusion criteria, IV tPA as compared to placebo given in the 3-to 4.5-hour window provided significantly improved clinical outcomes with acceptable risks of sICH and will no doubt change clinical practice. This extension of the time window can potentially increase the number of patients eligible for IV thrombolytics. However, since the more severe the stroke the earlier the patient presents to the emergency department, it is not clear how much the results of ECASS III will increase the number of stroke patients receiving tPA. Also, while effective out to 4.5 hours, it is important to underscore the importance of rapid treatment of AIS as it has been shown that clinical recovery is much more likely if treatment occurs within 2 hours of symptom onset. In 2008, the American Heart Association/ American Stroke Association released a science advisory recommending IV tPA in the 3-to 4.5-hour time window for eligible AIS patients, but the FDA
has not yet extended the label indication. In the meantime, most major stroke centers, including our own, have incorporated the ECASS III results into clinical practice but obtain informed consent of the off-label use of the drug in all patients treated beyond 3 hours.
PENUMBRAL IMAGING AND NEW THROMBO-LYTICS
Many stroke experts believe that the "time ϭ brain" concept for treating stroke is too simplistic, and that in many patients salvageable penumbral tissue may persist for many hours. Over the last 10 years, the use of perfusion imaging to identify such penumbral tissue in AIS has been an extremely active area of research. With the ability to identify salvageable tissue regardless of the time window, perfusion imaging can potentially improve patient selection and expand those eligible for thrombolysis. 10 Many clinical trials and stroke centers have incorporated penumbral imaging into their protocols despite the lack of consensus on the appropriate way to image the ischemic penumbra and the role for its use in patient selection.
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One such recently completed trial was Desmoteplase In Acute Ischemic Stroke 2 (DIAS-2).
The DIAS-2 trial was a randomized, placebocontrolled, double-blind, dose-ranging study using perfusion imaging (MRI or CT) for patient selection to evaluate the efficacy of the highly fibrin-specific plasminogen activator desmoteplase in AIS patients treated in the 3-to 9-hour time window. Patients aged 18 -85 years, with NIHSS 4 -24, who had potentially salvageable tissue (estimated as at least 20% more tissue with significantly reduced perfusion compared with the core of acute ischemic injury) 3-9 hours after symptom onset were eligible for the trial. 12 Treatments were allocated on a 1:1:1 ratio with patients receiving either 90 g/kg or 125 g/kg of desmoteplase or placebo. In total, 193 patients were randomized, with 186 receiving treatment (57 received 90 g/kg of desmoteplase, 64 received 125 g/kg of desmoteplase, 63 received placebo).
The primary efficacy endpoint was a composite 90-day outcome of improvement of NIHSS of 8 points or more from baseline or NIHSS Յ1, mRS of 0 -2, and Barthel Index of 75-100. Secondary endpoints were change in infarct volume from baseline to 30 days and individual components of the 90-day endpoints. The primary safety endpoints were symptomatic ICH defined as hemorrhage confirmed on imaging that led to an increase of 4 points or more in NIHSS at 72 hours, and 90-day mortality.
Demographics and baseline characteristics were similar between the 2 study groups and the placebo arm, with median NIHSS of 9 in all 3 arms, and comparable time to treatment. Clinical composite outcome at 90 days among the 3 treatment arms was not statistically different (composite responder rate: 90 g/kg desmoteplase 47%; 125 g/kg desmoteplase 36%; placebo 46%; p ϭ 0.47). Five sICH were observed in the study, all in the desmoteplase arms, with 2 in the 90 g/kg group and 3 in the 125 g/kg group. Mortality at 90 days was higher in the highdose desmoteplase arm with 14 deaths (21%) in the 125 g/kg group, 3 deaths (5%) in the 90 g/kg group, and 4 deaths (6%) in the placebo arm. Hemorrhage did not account for most of the deaths.
Unlike the earlier DIAS-1 and Dose Escalation of Desmoteplase in Acute Stroke (DEDAS) studies using similar image-based patient selection, DIAS-2 failed to show a favorable effect of desmoteplase given 3-9 hours after stroke onset. DIAS-2, however, did differ from the preceding 2 studies in that baseline NIHSS scores were lower 9 compared to a NIHSS of 12 for the DIAS and DEDAS studies. Consequently, placebo patients did much better than expected, and many patients who were enrolled probably did not have major arterial occlusion that would be advantageously treated by a lytic drug. Very importantly, the DIAS-2 investigators found that even though patients in DIAS-2 had higher mismatch volumes than patients in DIAS-1 or DEDAS, it did not translate into any noticeable benefit, bringing into question the predictive value of "mismatch" imaging. An ongoing follow-up study of desmoteplase has abandoned this image-based approach, and it is fair to say that a "tissue-based" approach as determined by imaging has yet to be proven superior than the "time-based" approach proven effective in the various tPA studies.
Another study also failed to show the benefit of a newer alternative to tPA. Tenecteplase (TNK), a modified version of tPA, is more fibrin-specific, with a longer half-life, allowing it to be given as a bolus instead of a 1-hour infusion like tPA. 13 Already approved for use in MI and observed to have less bleeding complications than tPA, TNK is a potential alternative to tPA for AIS as it is easier and possibly safer to administer. Prior TNK dose escalation studies showed similar clinical responses at 3 months when compared to tPA-treated patients; hence investigators moved onward and designed a phase IIB/III trial comparing IV TNK vs standard IV tPA in AIS patients within 3 hours of stroke onset hoping to find that it is a safer and at least as effective alternative.
This was a phase IIB/III multicenter, randomized, double-blind, controlled trial, and did not use any imaging selection other than plain head CT. The aims of the phase IIB study were to first establish the best dose of TNK to carry forward using an early clinical outcome measure and to provide data regard-ing the promise or futility of further testing of TNK vs tPA. Early clinical outcome was scored at 24 hours using a composite measure that balanced major neurologic improvement, defined as a Ն8-point improvement on the NIHSS or a score of 0 at 24 hours against the risk of sICH.
In total, 112 patients were randomized into the prematurely terminated trial, with 31 patients randomized to 0.1 mg/kg TNK, 31 patients randomized to 0.25 mg/kg TNK, 19 patients randomized to 0.4 mg/kg TNK, and 31 patients randomized to 0.9 mg/kg tPA. The 0.4 mg/kg TNK dose was discarded as inferior after only 73 patients were randomized, and the trial was terminated due to slow enrollment after 112 patients had been randomized. Analysis showed no statistical difference in the 3-month outcomes between the 2 remaining TNK doses and tPA, with insufficient data to confidently make any conclusion about efficacy or futility.
Despite attempts of recent trials like DIAS-2 and the TNK study to demonstrate superiority of newer lytics over tPA, tPA remains the only proven effective thrombolytic. The value of penumbral imaging has not yet been proven, with many controversies surrounding standardization of perfusion thresholding and imaging/postprocessing techniques. 11 Until another proven therapy comes along, and we learn how to select patients who may qualify at later time windows, the focus of the stroke community should be on increasing the number of patients treated early with tPA, educating clinicians, emergency medical services, and hospitals to improve administration rates, and finding ways to amplify tPA when given in the ultra-early time frame.
ADVANCES IN POSTSTROKE CARE Hyperglycemia and its association with poor stroke outcome has been reported in animal models and in humans. 14 However, evidence is lacking regarding the therapeutic benefits of tight glycemic control in the AIS population. The Glucose Regulation in Acute Stroke Patients (GRASP) trial was a prospective randomized 3-arm trial that aimed to assess the safety and feasibility of tight glycemic control using 2 insulin infusion protocols in AIS patients. Enrolled patients were randomized into a tight control arm (target glucose 70 -100 mg/dL), loose control arm (target glucose 70 -200 mg/dL), or usual care control arm (target glucose 70 -300 mg/dL).
A total of 74 patients were enrolled, with 25 patients randomized into the usual care arm, 25 patients randomized into the loose control arm, and 24 patients randomized into the tight control arm. The primary endpoints were safety, determined by hypoglycemia (blood glucose Ͻ55 mg/dL), symptomatic hypoglycemia, and feasibility determined by intarget success at 24 hours.
Results showed that hypoglycemia was more common in the tight control arm, with 30% of the patients experiencing at least 1 episode compared to only 4% in the loose and usual care arms. Symptomatic hypoglycemia was detected in only 1 patient (from the loose control arm). The median glucose in the tight control arm during the study period was 111 mg/dL, with 44% meeting glucose target at 24 hours compared to the loose control arm, with a median glucose of 151 mg/dL and 92% meeting glucose target at 24 hours. In the usual care arm, 88% met target glucose with a median glucose of 151 mg/dL. Designed as a pilot safety and feasibility study, the study was not powered to detect clinical benefit between the treatment arms.
Although nonsignificant and requiring further study, GRASP casts doubt on the benefit and safety of tight glycemic control in AIS, and underscores again that stroke patients are a unique population, and that therapeutics cannot be generalized from another organ system to cerebrovascular disease.
CONCLUSION Stroke treatment and prevention can make a major difference in the effect of stroke on the individual patient and on societal costs. Within the last 2 years, a number of trials summarized here have or may soon lead to changes in clinical practice. It is important not only to continue to strive to find more effective treatment and prevention strategies for ischemic stroke, but also to work to accomplish the systematic changes to help implement these strategies.
